Skip to main content
Caplight Logo









enGenome

enGenome

Private
PaviaHealthcare & Life Scienceshttps://engenome.com/

Last Round

Accelerator

Oct 14, 2021

Total Funding Raised

$4.29M

Company Overview

enGenome is a bioinformatics company that provides an AI-powered software platform for genomic data analysis and interpretation to support the diagnosis of genetic diseases.

Sector

Healthcare & Life Sciences

Verticals

Medical AI, Precision Medicine, Biotechnology, NLP & Conversational AI, Healthcare Analytics

Business Model

B2B

Customer Profile

Subscription SaaS, Services & Consulting, Freemium

AI Layer

Application

Keywords

genomic data interpretationAI for genomicsvariant interpretationrare disease diagnosisbioinformatics platformNGS data analysisvariant classificationhereditary diseaseACMG guidelinesclinical decision supportCE-IVD softwareexplainable AIXAIgenerative AIgenomic literature searchbioinformatics consulting

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

enGenome Comparables

Compare enGenome with similar companies based on industry and business-model similarity.

enGenome comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Limbus Medical Technologies
88%
Saphetor
88%
SeqOne
82%

enGenome Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
AcceleratorOct 14, 2021

Key People

Founding team and executive leadership

Ivan Limongelli

CTO & Co Founder

Founding Team

Ettore Rizzo

CEO and Co Founder

Founding Team

enGenome Investors

Notable investors and investment history

enGenome investors
InvestorRounds
European Innovation Council FundAccelerator

Market signals

Structured signals derived from secondary market and firmographic data.

  • Dec 9, 2025

    Monthly visitors increased 64% MoM, reaching 5.8K.

  • Jun 1, 2025

    Monthly visitors increased 41% MoM, reaching 3.1K.

enGenome Filings

Explore SEC and related filing metadata, where available.

enGenome filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about enGenome's valuation, stock price, and market status.

Is enGenome a public or private company?

enGenome is a private company.

What is the current stock price of enGenome?

enGenome is a private company with no public stock price. No recent secondary market data is available.

How much is enGenome worth (valuation)?

Valuation information for enGenome is not publicly available.

Can I buy enGenome stock?

enGenome shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was enGenome's last funding round?

enGenome's most recent funding round was Accelerator on October 14, 2021.

Who are the main investors in enGenome?

Key investors in enGenome include European Innovation Council Fund.

Will enGenome IPO soon?

No public IPO plans have been announced for enGenome.

How can I track enGenome secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor enGenome's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersPavia
Employee Range23
Year Founded2016
Last FundingOct 14, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?